Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain.
暂无分享,去创建一个
[1] D. Mash,et al. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain , 2003, Neuropharmacology.
[2] I. Björkhem,et al. Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain , 2006, Journal of internal medicine.
[3] Volk,et al. Testosterone Metabolism In Rat Brain Is Differentially Enhanced By Phenytoin‐Inducible Cytochrome P450 Isoforms , 1999, Journal of neuroendocrinology.
[4] R. Lathe,et al. Cyp7b, a novel brain cytochrome P450, catalyzes the synthesis of neurosteroids 7α-hydroxy dehydroepiandrosterone and 7α-hydroxy pregnenolone , 1997 .
[5] M. Negishi,et al. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. , 2000, The Biochemical journal.
[6] T. Bayer,et al. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease Published, JLR Papers in Press, October 1, 2003. DOI 10.1194/jlr.M300320-JLR200 , 2004, Journal of Lipid Research.
[7] M. Boyd,et al. A Frameshift Mutation and Alternate Splicing in Human Brain Generate a Functional Form of the Pseudogene Cytochrome P4502D7 That Demethylates Codeine to Morphine* , 2004, Journal of Biological Chemistry.
[8] T. Slotkin. Guidelines for developmental neurotoxicity and their impact on organophosphate pesticides: a personal view from an academic perspective. , 2004, Neurotoxicology.
[9] S. Imaoka,et al. Dopamine formation from tyramine by CYP2D6. , 1998, Biochemical and biophysical research communications.
[10] F. Bergquist,et al. Inhibition of cytochrome P450 2E1 induces an increase in extracellular dopamine in rat substantia nigra: A new metabolic pathway? , 2001, Synapse.
[11] R. Rawbone,et al. Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes. , 2000, Toxicology letters.
[12] V. Ravindranath,et al. Constitutive expression and localization of cytochrome P‐450 1A1 in rat and human brain: presence of a splice variant form in human brain 1 , 2005, Journal of neurochemistry.
[13] J. Idle,et al. The Relative Contribution of Monoamine Oxidase and Cytochrome P450 Isozymes to the Metabolic Deamination of the Trace Amine Tryptamine , 2003, Journal of Pharmacology and Experimental Therapeutics.
[14] M. Boyd,et al. Expression of multiple forms of cytochrome P450 and associated mono-oxygenase activities in rat brain regions. , 1998, Biochemical pharmacology.
[15] Ernest Hodgson,et al. In vitro human phase I metabolism of xenobiotics I: Pesticides and related compounds used in agriculture and public health, may 2003 , 2003, Journal of biochemical and molecular toxicology.
[16] V. Ravindranath,et al. Alternative splicing within the human cytochrome P450 superfamily with an emphasis on the brain: the convolution continues , 2006, Expert opinion on drug metabolism & toxicology.
[17] A. Somogyi,et al. Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia. , 1990, Life sciences.
[18] H. Checkoway,et al. Epidemiologic approaches to the study of Parkinson's disease etiology. , 1999, Epidemiology.
[19] J. Schenkman,et al. Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. , 2005, Archives of biochemistry and biophysics.
[20] J. Yager,et al. Tissue-specific synthesis and oxidative metabolism of estrogens. , 2000, Journal of the National Cancer Institute. Monographs.
[21] S. Auriola,et al. Kinetic characteristics of norcocaine N-hydroxylation in mouse and human liver microsomes: involvement of CYP enzymes , 2000, Archives of Toxicology.
[22] Sharon Miksys,et al. Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics , 2003, British journal of pharmacology.
[23] P. Fritz,et al. Distribution and Cellular Localization of Prostacyclin Synthase in Human Brain , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[24] M. Mattson,et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[25] S. Shankar,et al. NADPH cytochrome P-450 reductase in rat, mouse and human brain. , 1990, Biochemical pharmacology.
[26] R. Tyndale,et al. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. , 2003, Molecular pharmacology.
[27] C. Elger,et al. Messenger RNA of steroid 21-hydroxylase (CYP21) is expressed in the human hippocampus , 2001, Neuroscience Letters.
[28] F. Guengerich,et al. Radical cation intermediates in N-dealkylation reactions. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.
[29] F Peter Guengerich,et al. Cytochrome P450: What Have We Learned and What Are the Future Issues? , 2004, Drug metabolism reviews.
[30] S. Creighton,et al. Identification of the human cytochrome P450, P450RAI-2, which is predominantly expressed in the adult cerebellum and is responsible for all-trans-retinoic acid metabolism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[31] S. Ceccatelli,et al. Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the expression of cytochrome P450 1A1, the aryl hydrocarbon receptor, and the aryl hydrocarbon receptor nuclear translocator in rat brain and pituitary. , 2000, Toxicology and applied pharmacology.
[32] R. Martins,et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease , 2006, Molecular Psychiatry.
[33] R. Tyndale,et al. Drug-metabolizing cytochrome P450s in the brain. , 2002, Journal of psychiatry & neuroscience : JPN.
[34] F. Oesch,et al. Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine (‘Ecstasy’) cytotoxicity , 2006, Pharmacogenetics and genomics.
[35] G. Siest,et al. Subcellular distribution of cytochrome P-450 in the brain , 1986, Brain Research.
[36] Anna M. Lee,et al. Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein , 2006, British journal of pharmacology.
[37] B. Stoffel‐Wagner. Neurosteroid metabolism in the human brain. , 2001, European journal of endocrinology.
[38] C. J. Omiecinski,et al. Activation of cytochrome P450 gene expression in the rat brain by phenobarbital-like inducers. , 2000, The Journal of pharmacology and experimental therapeutics.
[39] Eric A Newman,et al. Glial Cells Dilate and Constrict Blood Vessels: A Mechanism of Neurovascular Coupling , 2006, The Journal of Neuroscience.
[40] J M Guileyardo,et al. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[41] M. Taimi,et al. CYP2U1, a Novel Human Thymus- and Brain-specific Cytochrome P450, Catalyzes ω- and (ω-1)-Hydroxylation of Fatty Acids* , 2004, Journal of Biological Chemistry.
[42] M. Eichelbaum,et al. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. , 2001, Pharmacogenetics.
[43] Yifu Deng,et al. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease , 2004, Annals of neurology.
[44] C. Eckman,et al. Differential Expression of Cholesterol Hydroxylases in Alzheimer's Disease* , 2004, Journal of Biological Chemistry.
[45] C. Thompson,et al. Cytochromes P450 in brain: function and significance. , 2001, Current drug metabolism.
[46] M. Eichelbaum,et al. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation , 1998, Pain.
[47] J. Goldstein,et al. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs , 1999, Journal of biochemical and molecular toxicology.
[48] A. Kappas,et al. On the occurrence of cytochrome P-450 and aryl hydrocarbon hydroxylase activity in rat brain , 1977, The Journal of experimental medicine.
[49] L. Bertilsson,et al. Relationship between personality and debrisoquine hydroxylation capacity , 1993, Acta psychiatrica Scandinavica.
[50] J. Idle,et al. Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. , 2003, Pharmacogenetics.
[51] C. J. Omiecinski,et al. Regiospecific expression of cytochrome P-450s and microsomal epoxide hydrolase in human brain tissue. , 1993, Journal of toxicology and environmental health.
[52] G. Celesia,et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.
[53] N. Alkayed,et al. Cytochrome P450 in neurological disease. , 2004, Current drug metabolism.
[54] P. Jenner,et al. P450 enzymes and Parkinson's disease: The story so far , 1998, Movement disorders : official journal of the Movement Disorder Society.
[55] K. Husgafvel‐Pursiainen,et al. CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour. , 2000, Pharmacogenetics.
[56] M. Boyd,et al. Multiple forms of cytochrome P450 and associated monooxygenase activities in human brain mitochondria. , 2000, Biochemical pharmacology.
[57] H. Kölsch,et al. Neurotoxicity of 24-hydroxycholesterol, an important cholesterol elimination product of the brain, may be prevented by vitamin E and estradiol-17β , 2001, Journal of Neural Transmission.
[58] J. Kraner,et al. Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA). , 2001, Journal of analytical toxicology.
[59] C. Gomez-Sanchez,et al. Steroidogenic enzyme gene expression in the human brain , 2002, Molecular and Cellular Endocrinology.
[60] I. Pikuleva. CHOLESTEROL-METABOLIZING CYTOCHROMES P450 , 2006, Drug Metabolism and Disposition.
[61] J. McGrath,et al. Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain , 2005, Journal of Chemical Neuroanatomy.
[62] Xiaochao Ma,et al. METABOLISM OF MELATONIN BY HUMAN CYTOCHROMES P450 , 2005, Drug Metabolism and Disposition.
[63] S. Shankar,et al. Microsomal cytochrome P450 in human brain regions. , 1992, Biochemical pharmacology.
[64] D. Kusewitt,et al. In Situ Hybridization and Immunohistochemical Analysis of Cytochrome P450 1B1 Expression in Human Normal Tissues , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[65] V. Hans,et al. Characterization of the dehydroepiandrosterone (DHEA) metabolism via oxysterol 7α‐hydroxylase and 17‐ketosteroid reductase activity in the human brain , 2002, Journal of neurochemistry.
[66] S. Imaoka,et al. Progesterone oxidation by cytochrome P450 2D isoforms in the brain. , 2001, Endocrinology.
[67] Schramm,et al. Sex‐ and Age‐Specific Differences in Human Brain CYP11A1 mRNA Expression , 1999, Journal of neuroendocrinology.
[68] Ulrich M. Zanger,et al. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.
[69] Sharon Miksys,et al. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics , 2002, Journal of neurochemistry.
[70] A. Gaedigk,et al. CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein? , 2005, Biochemical and biophysical research communications.
[71] A. Williams,et al. Cytochrome P450 1B1 mRNA in the human central nervous system. , 1998, Molecular pathology : MP.
[72] M. Ames,et al. Cytochrome P-450 and NADPH cytochrome c reductase in rat brain: formation of catechols and reactive catechol metabolites. , 1977, Biochemical and biophysical research communications.
[73] L. Sayre,et al. Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl)propane. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[74] Anna M. Lee,et al. CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment , 2006, Neuropharmacology.
[75] R. Pohjanvirta,et al. Effect of TCDD on mRNA expression of genes encoding bHLH/PAS proteins in rat hypothalamus. , 2005, Toxicology.
[76] R. Poulsom,et al. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.
[77] I. Hindmarch. Beyond the monoamine hypothesis: mechanisms, molecules and methods , 2002, European Psychiatry.
[78] R. Tyndale,et al. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. , 1991, Molecular pharmacology.
[79] S. Mellon,et al. Neurosteroids: biochemistry and clinical significance , 2002, Trends in Endocrinology & Metabolism.
[80] M. Boyd,et al. Cytochrome P4502E (CYP2E) in brain: constitutive expression, induction by ethanol and localization by fluorescence in situ hybridization. , 2000, Archives of biochemistry and biophysics.
[81] K. Ukena,et al. Novel brain function: biosynthesis and actions of neurosteroids in neurons , 2000, Neuroscience Research.
[82] G. Tucker,et al. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[83] R. Tyndale,et al. The Unique Regulation of Brain Cytochrome P450 2 (CYP2) Family Enzymes by Drugs and Genetics , 2004, Drug metabolism reviews.
[84] Tetsuo Satoh,et al. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. , 2003, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
[85] R. Tyndale,et al. Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[86] K. Kreth,et al. Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. , 2000, Biochemical pharmacology.
[87] A. Llerena,et al. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients , 2007, The Pharmacogenomics Journal.
[88] J. Gustafsson,et al. Regional Distribution of Cytochrome P‐450 in the Rat Brain: Spectral Quantitation and Contribution of P‐450b,e and P‐450c,d , 1988, Journal of neurochemistry.
[89] H Jick,et al. Statins and the risk of dementia , 2000, The Lancet.
[90] D. Zeldin,et al. Variability of CYP2J2 Expression in Human Fetal Tissues , 2006, Journal of Pharmacology and Experimental Therapeutics.
[91] A. Beaudet,et al. Vitamin E protects hypothalamic beta-endorphin neurons from estradiol neurotoxicity. , 1992, Endocrinology.
[92] P. Wedlund,et al. Cytochrome P-450 in the brain. Potential evolutionary and therapeutic relevance of localization of drug-metabolizing enzymes. , 1992, Drug metabolism and disposition: the biological fate of chemicals.
[93] E. Hodgson. In vitro human phase I metabolism of xenobiotics I: Pesticides and related chemicals used in agriculture and public health, September 2001 , 2001, Journal of biochemical and molecular toxicology.
[94] C. J. Omiecinski,et al. Regional distribution and expression modulation of cytochrome P-450 and epoxide hydrolase mRNAs in the rat brain. , 1993, Molecular pharmacology.
[95] M. Boyd,et al. Characterization of a phenobarbital-inducible cytochrome P-450, NADPH-cytochrome P-450 reductase and reconstituted cytochrome P-450 mono-oxygenase system from rat brain. Evidence for constitutive presence in rat and human brain. , 1992, The Biochemical journal.
[96] C. Bouras,et al. Cytochrome P-450 activities in human and rat brain microsomes , 2000, Brain Research.
[97] T. Baillie,et al. Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. , 1987, Science.
[98] Y. Funae,et al. CYP2D in the brain. , 2003, Drug metabolism and pharmacokinetics.
[99] M. Boyd,et al. Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain. , 2002, Brain research. Molecular brain research.
[100] G. Gordon Gibson,et al. Introduction to Drug Metabolism , 1986, Springer US.
[101] R. Tyndale,et al. Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. , 2000, Journal of clinical psychopharmacology.
[102] A. Somogyi,et al. Precipitated withdrawal following codeine administration is dependent on CYP genotype. , 2001, European journal of pharmacology.
[103] C. Caltagirone,et al. Genetic correlates of behavioral endophenotypes in Alzheimer disease: Role of COMT, 5-HTTLPR and APOE polymorphisms , 2006, Neurobiology of Aging.
[104] H. Sasano,et al. Aromatase in the human central nervous system , 1998, Clinical endocrinology.
[105] J. Hallas,et al. The relationship between paroxetine and the sparteine oxidation polymorphism , 1992, Clinical pharmacology and therapeutics.
[106] Christophe Tzourio,et al. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease , 2004, Annals of neurology.
[107] K. Reuhl,et al. Constitutive and inducible levels of CYP1A1 and CYP1A2 in rat cerebral cortex and cerebellum , 2003, Archives of Toxicology.
[108] M. Ingelman-Sundberg,et al. Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1. , 2004, Biochemical and biophysical research communications.
[109] C. Elger,et al. Expression of cytochrome P450scc mRNA in the hippocampus of patients with temporal lobe epilepsy. , 1999, Neuroreport.
[110] G. Murray,et al. Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. , 1998, Biochemical pharmacology.
[111] E. Masliah,et al. Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells. , 2003, Gene Expression.
[112] G. Siest,et al. Dextromethorphan O-demethylase activity in rat brain microsomes , 1995, Neuroscience Letters.
[113] T. Yokoi,et al. Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. , 2004, Drug metabolism and pharmacokinetics.
[114] E. Kojro,et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10 , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[115] D. Rozman,et al. Mammalian cytochromes P450--importance of tissue specificity. , 2007, Biochimica et biophysica acta.
[116] S. Imaoka,et al. Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. , 2004, Endocrinology.
[117] M. Juchau,et al. Expression of cytochrome P450RAI (CYP26) in human fetal hepatic and cephalic tissues. , 1998, Biochemical and biophysical research communications.
[118] L. Thal,et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology , 2003, Neurology.
[119] T. Hicks,et al. The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain , 2006, Progress in Neurobiology.
[120] H. Issaq,et al. Nicotine metabolism and CYP2D6 phenotype in smokers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[121] S. Khuder,et al. A meta-analysis of Parkinson's disease and exposure to pesticides. , 2000, Neurotoxicology.
[122] E. Sellers,et al. Interactions of amphetamine analogs with human liver CYP2D6. , 1997, Biochemical pharmacology.
[123] R. Tyndale,et al. Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. , 2000, Biochemical pharmacology.
[124] B. Strooper,et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[125] G. Murray,et al. Cytochrome P450 CYP3A5 in the human anterior pituitary gland , 1995, FEBS letters.
[126] W. Miller. Disorders of Androgen Synthesis – from Cholesterol to Dehydroepiandrosterone , 2005, Medical Principles and Practice.
[127] W. J. Brooks,et al. Astrocytes as a primary locus for the conversion MPTP into MPP+ , 1989, Journal of Neural Transmission.